Please use this identifier to cite or link to this item:
http://hdl.handle.net/1843/50646
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Débora Priscila de Campos | pt_BR |
dc.creator | Neila Márcia Silva Barcellos | pt_BR |
dc.creator | Renata Rodrigues Lima | pt_BR |
dc.creator | Ranylson Marcello Leal Savedra | pt_BR |
dc.creator | Melissa Fabíola Siqueira | pt_BR |
dc.creator | Maria Irene Yoshida | pt_BR |
dc.creator | Wagner da Nova Mussel | pt_BR |
dc.creator | Jacqueline de Souza | pt_BR |
dc.date.accessioned | 2023-03-03T17:59:36Z | - |
dc.date.available | 2023-03-03T17:59:36Z | - |
dc.date.issued | 2018-10 | - |
dc.citation.volume | 19 | pt_BR |
dc.citation.issue | 7 | pt_BR |
dc.citation.spage | 3019 | pt_BR |
dc.citation.epage | 3028 | pt_BR |
dc.identifier.doi | https://doi.org/10.1208/s12249-018-1129-6 | pt_BR |
dc.identifier.issn | 1530-9932 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/1843/50646 | - |
dc.description.resumo | The recommended method for the biopharmaceutical evaluation of drug solubility is the shake flask; however, there are discrepancies reported about the solubility of certain compounds measured with this method, one of them is candesartan cilexetil. The present work aimed to elucidate the solubility of candesartan cilexetil by associating others assays such as stability determination, polymorphic characterization and in silico calculations of intrinsic solubility, ionized species, and electronic structures using quantum chemistry descriptors (frontier molecular orbitals and Fukui functions). For the complete biopharmaceutical classification, we also reviewed the permeability data available. The polymorphic form used was previously identified as the form I of candesartan cilexetil. The solubility was evaluated in biorelevant media in the pH range of 1.2–6.8 at 37.0°C according to the stability previously assessed. The solubility of candesartan cilexetil is pH dependent and the dose/solubility ratios obtained demonstrated the low solubility of the prodrug. The in silico calculations supported the found results and evidenced the main groups involved in the solvation, benzimidazole, and tetrazol-biphenyl. The human absolute bioavailability reported demonstrates that candesartan cilexetil has low permeability and when associated with the low solubility allows to classify it as class 4 of the Biopharmaceutics Classification System. | pt_BR |
dc.description.sponsorship | CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico | pt_BR |
dc.description.sponsorship | FAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais | pt_BR |
dc.description.sponsorship | CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior | pt_BR |
dc.description.sponsorship | Outra Agência | pt_BR |
dc.language | eng | pt_BR |
dc.publisher | Universidade Federal de Minas Gerais | pt_BR |
dc.publisher.country | Brasil | pt_BR |
dc.publisher.department | ICX - DEPARTAMENTO DE QUÍMICA | pt_BR |
dc.publisher.initials | UFMG | pt_BR |
dc.rights | Acesso Restrito | pt_BR |
dc.subject | Polymorphism | pt_BR |
dc.subject | Quantum chemistry | pt_BR |
dc.subject | Biopharmaceutics classification cystem | pt_BR |
dc.subject | Equilibrium solubility | pt_BR |
dc.subject | Candesartan cilexetil | pt_BR |
dc.subject.other | Química quântica | pt_BR |
dc.subject.other | Físico-química | pt_BR |
dc.subject.other | Polimorfismo (Cristalografia) | pt_BR |
dc.subject.other | Solubilidade | pt_BR |
dc.subject.other | Permeabilidade | pt_BR |
dc.subject.other | Medicamentos - Estabilidade | pt_BR |
dc.subject.other | Agentes hipotensores | pt_BR |
dc.subject.other | Biofarmacêutica | pt_BR |
dc.subject.other | Fármacos - Classificação | pt_BR |
dc.subject.other | Solvação | pt_BR |
dc.subject.other | Orbitais moleculares | pt_BR |
dc.subject.other | Análise térmica | pt_BR |
dc.subject.other | Raios X - Difração | pt_BR |
dc.title | Polymorphic and quantum chemistry characterization of candesartan cilexetil: importance for the correct drug classification according to biopharmaceutics classification system | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.url.externa | https://link.springer.com/article/10.1208/s12249-018-1129-6 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0003-3619-5965 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0003-0013-9937 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0002-4809-577X | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0002-0277-0418 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0002-6795-9457 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0002-9768-9830 | pt_BR |
dc.identifier.orcid | https://orcid.org/0000-0003-0869-023X | pt_BR |
Appears in Collections: | Artigo de Periódico |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.